News
-
After announcing a deal with Recipharm for development of two inhaled drugs (TRB-1 and TRB-2) earlier this year, Transpire Bio says that it has signed an agreement with the CDMO for development of an additional… Read more . . .
-
Ocugen announced that it has acquired US, European, and Japanese rights to an intranasal COVID-19 vaccine developed at Washington University in St. Louis. In September 2020, Bharat Biotech announced that it had acquired rights to… Read more . . .
-
According to Qnovia, which recently changed its name from Respira Technologies, the company has closed a $17 million Series A financing round led by Blue Ledge Capital, with the funds intended to support development of… Read more . . .
-
According to Atrium Health Wake Forest Baptist, Wake Forest University School of Medicine has received a two-year $795,000 grant from the Alzheimer’s Association to support a Phase 2 trial of empagliflozin and intranasal insulin for… Read more . . .
-
RS BioTherapeutics, which recently announced positive results from a proof of concept study of its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) in a mouse model, said that the company has raised $3 million in a Seed… Read more . . .
-
According to inhalation CDMO Vectura, the company been granted planning permission to build a new £58 million, 10,000 sq m facility in Southwest England to house the company’s Inhalation Centre of Excellence, with construction expected… Read more . . .
-
CDMO and device maker Recipharm has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as a member, the company announced. Recipharm will be represented on the IPAC-RS Board by Head of Commercial… Read more . . .
-
According to Bausch Health and Glenmark, Health Canada has approved Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in people aged 6 and older. Bausch Health acquired the Canadian rights… Read more . . .
-
On a form 8-k filed with the US Securities and Exchange Commission (SEC), United Therapeutics reported the following: “On September 20, 2022, United Therapeutics Corporation (the Company) announced the termination of the PERFECT clinical study… Read more . . .
-
OINDP development specialist Nanopharm, which was acquired by Aptar Pharma in 2019, and functional respiratory imaging (FRI) company Fluidda are teaming up to help sponsors of ANDAs for inhaled drugs for asthma and COPD avoid… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.